LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)

Oncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as...

Full description

Saved in:
Bibliographic Details
Main Authors: M. L. Kazantseva, E. V. Oshchepkova, M. A. Saidova, A. A. Avalyan, I. F. Chazova
Format: Article
Language:Russian
Published: InterMedservice 2019-09-01
Series:Евразийский Кардиологический Журнал
Subjects:
Online Access:https://www.heartj.asia/jour/article/view/337
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849245056434700288
author M. L. Kazantseva
E. V. Oshchepkova
M. A. Saidova
A. A. Avalyan
I. F. Chazova
author_facet M. L. Kazantseva
E. V. Oshchepkova
M. A. Saidova
A. A. Avalyan
I. F. Chazova
author_sort M. L. Kazantseva
collection DOAJ
description Oncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as well as to the development and implementation of new technologies and therapeutic treatment strategies (chemotherapy, targeted and radiation therapy). Among patients with OD who received chemotherapy and radiation therapy, CVD is one of the leading causes of poor prognosis, including lethal outcomes [2-5]. The long-term cardiotoxic effects of antitumor therapy (chemotherapy, radiation therapy) reduce the survival rate and quality of life of patients who suffer from cancer. Thus, early diagnostics and timely detection of the cardiotoxic effects that follow antitumor treatment is one of the main tasks of cardio-oncology.
format Article
id doaj-art-488693a33f5848b08fd9182f34f2e866
institution Kabale University
issn 2225-1685
2305-0748
language Russian
publishDate 2019-09-01
publisher InterMedservice
record_format Article
series Евразийский Кардиологический Журнал
spelling doaj-art-488693a33f5848b08fd9182f34f2e8662025-08-20T03:58:56ZrusInterMedserviceЕвразийский Кардиологический Журнал2225-16852305-07482019-09-0103506410.38109/2225-1685-2019-3-50-64336LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)M. L. Kazantseva0E. V. Oshchepkova1M. A. Saidova2A. A. Avalyan3I. F. Chazova4A.L. Myasnikov Clinical Cardiology Institute Federal State Budgetary Institution «National Medical Research Center of Cardiology,» Russian Ministry of HealthcareA.L. Myasnikov Clinical Cardiology Institute Federal State Budgetary Institution «National Medical Research Center of Cardiology,» Russian Ministry of HealthcareA.L. Myasnikov Clinical Cardiology Institute Federal State Budgetary Institution «National Medical Research Center of Cardiology,» Russian Ministry of HealthcareA.L. Myasnikov Clinical Cardiology Institute Federal State Budgetary Institution «National Medical Research Center of Cardiology,» Russian Ministry of HealthcareA.L. Myasnikov Clinical Cardiology Institute Federal State Budgetary Institution «National Medical Research Center of Cardiology,» Russian Ministry of HealthcareOncological and cardiovascular diseases (CVD) hold a leading position among the causes of mortality in many countries of the world, including the Russian Federation [1]. In recent years, a decrease in mortality due to oncologic diseases (OD) is noted around the world thanks to early diagnostics, as well as to the development and implementation of new technologies and therapeutic treatment strategies (chemotherapy, targeted and radiation therapy). Among patients with OD who received chemotherapy and radiation therapy, CVD is one of the leading causes of poor prognosis, including lethal outcomes [2-5]. The long-term cardiotoxic effects of antitumor therapy (chemotherapy, radiation therapy) reduce the survival rate and quality of life of patients who suffer from cancer. Thus, early diagnostics and timely detection of the cardiotoxic effects that follow antitumor treatment is one of the main tasks of cardio-oncology.https://www.heartj.asia/jour/article/view/337cardio-oncologycardiotoxicityarterial hypertensionheart failureoncologyspeckle tracking technologyradiation therapychemotherapy
spellingShingle M. L. Kazantseva
E. V. Oshchepkova
M. A. Saidova
A. A. Avalyan
I. F. Chazova
LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)
Евразийский Кардиологический Журнал
cardio-oncology
cardiotoxicity
arterial hypertension
heart failure
oncology
speckle tracking technology
radiation therapy
chemotherapy
title LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)
title_full LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)
title_fullStr LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)
title_full_unstemmed LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)
title_short LONG-TERM CARDIOVASCULAR COMPLICATIONS IN ONCOLOGIC PATIENTS AFTER ANTITUMOR THERAPY (>1 YEAR)
title_sort long term cardiovascular complications in oncologic patients after antitumor therapy 1 year
topic cardio-oncology
cardiotoxicity
arterial hypertension
heart failure
oncology
speckle tracking technology
radiation therapy
chemotherapy
url https://www.heartj.asia/jour/article/view/337
work_keys_str_mv AT mlkazantseva longtermcardiovascularcomplicationsinoncologicpatientsafterantitumortherapy1year
AT evoshchepkova longtermcardiovascularcomplicationsinoncologicpatientsafterantitumortherapy1year
AT masaidova longtermcardiovascularcomplicationsinoncologicpatientsafterantitumortherapy1year
AT aaavalyan longtermcardiovascularcomplicationsinoncologicpatientsafterantitumortherapy1year
AT ifchazova longtermcardiovascularcomplicationsinoncologicpatientsafterantitumortherapy1year